Sunitinib Malate

A Global Strategic Business Report

MCP15073

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

2902

EXECUTIVE POOL

5850

PRICE

522

EXPERT INPUTS

44

COMPANIES

123

DATA TABLES

193

PAGES

8

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (1184)

34

CXO

59

VICE PRESIDENT

367

DIRECTOR

476

MANAGER

248

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Sunitinib Malate Market to Reach US$232.0 Million by 2030

The global market for Sunitinib Malate estimated at US$133.7 Million in the year 2024, is expected to reach US$232.0 Million by 2030, growing at a CAGR of 9.6% over the analysis period 2024-2030. Pancreatic Neuroendocrine Tumor Application, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$111.6 Million by the end of the analysis period. Growth in the Gastrointestinal Stromal Tumor Application segment is estimated at 7.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$35.7 Million While China is Forecast to Grow at 8.6% CAGR

The Sunitinib Malate market in the U.S. is estimated at US$35.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$35.2 Million by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.6% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global Sunitinib Malate Market - Key Trends and Drivers Summarized

Why Is Sunitinib Malate a Key Player in Targeted Cancer Therapies?

Sunitinib Malate, an oral multi-kinase inhibitor, plays a pivotal role in the treatment of various types of cancer, including renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST). As one of the key drugs in targeted therapy, Sunitinib works by inhibiting multiple pathways involved in tumor growth, including angiogenesis, proliferation, and metastasis. Approved by the FDA for its efficacy in treating advanced kidney cancer and other malignancies, Sunitinib offers a lifeline for patients who do not respond well to conventional chemotherapy. Its ability to block vascular endothelial growth factors (VEGFR) and platelet-derived growth factor receptors (PDGFR) has positioned it as a cornerstone in the targeted oncology market. The rising incidence of cancer and the growing demand for personalized medicine have driven the adoption of Sunitinib in oncology.

What Are the Innovations Shaping the Future of Sunitinib Malate?

Recent advancements in precision medicine have opened up new avenues for Sunitinib Malate in the treatment of rare and hard-to-treat cancers. Research is focusing on combining Sunitinib with other immunotherapies to enhance treatment efficacy and overcome drug resistance. Additionally, the development of biomarkers is helping oncologists identify patients who would benefit the most from Sunitinib therapy, thus improving treatment outcomes. Ongoing clinical trials are exploring its applications in combination with checkpoint inhibitors, showing promising results in extending patient survival rates. However, challenges such as drug resistance and side effects like hypertension and fatigue have spurred further research into improving the safety profile of Sunitinib without compromising its effectiveness.

Which Market Segments Are Leading for Sunitinib Malate?

The largest segment remains renal cell carcinoma (RCC), as Sunitinib is a first-line treatment for advanced and metastatic forms of this cancer. The drug is also gaining traction in the gastrointestinal stromal tumor (GIST) treatment market, particularly among patients who do not respond to imatinib. Regionally, North America holds the largest market share due to high cancer prevalence, favorable reimbursement policies, and a strong pharmaceutical infrastructure. Europe follows closely, driven by advancements in cancer treatment and clinical research. Meanwhile, emerging markets in Asia-Pacific are witnessing rapid growth in demand, fueled by increasing cancer rates and improving healthcare access.

What Is Driving Growth in the Sunitinib Malate Market?

The growth in the Sunitinib Malate market is driven by several factors, including the rising incidence of renal cell carcinoma and gastrointestinal stromal tumors, increasing adoption of targeted therapies, and advancements in precision oncology. Growing investments in cancer research and the development of combination therapies are expanding the drug’s application, particularly in metastatic cancers. Additionally, the expanding approval of Sunitinib for rare cancer indications, along with the growth of clinical trials in emerging markets, is boosting market penetration. The increasing healthcare expenditure and enhanced access to oncology treatments in developing regions are further accelerating market expansion.

SCOPE OF STUDY

The report analyzes the Sunitinib Malate market by the following Segments, and Geographic Regions/Countries:

Segments:

Purity Level (Above 99% Purity, Above 98% Purity, Above 97% Purity); Application (Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application, Kidney Cancer Application).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

Active Biotech AB; Astellas Pharma, Inc.; Bristol-Myers Squibb Company; Changzhou Highassay Chemical Co., Ltd; Dendreon Pharmaceuticals LLC; Ferring Pharmaceuticals Inc; Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.; Medichem, S.A.; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

Tariff Impact on Global Supply Chain Patterns

Global Economic Update

Sunitinib Malate – Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 44 Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Prevalence of Cancer Drives Demand for Sunitinib Malate in Oncology Treatments

Expansion of Targeted Therapies in Cancer Treatment Spurs Growth in Sunitinib Malate Market

Increased FDA Approvals for New Cancer Indications Expands Addressable Market Opportunity

Advancements in Precision Medicine Strengthen the Business Case for Sunitinib Malate

Rising Demand for Personalized Cancer Treatments Generates Market Growth

Emerging Clinical Trials for Combination Therapies Propels Market Competitiveness

Challenges Related to Drug Resistance in Cancer Treatments Create Opportunities for New Developments

Rising Investments in Cancer Research Accelerates Demand for Targeted Therapies

Increasing Focus on Orphan Drug Development Throws Spotlight on Sunitinib Malate

Growing Application in Metastatic Cancer Treatments Sustains Market Growth

Emergence of Biosimilars in Oncology Pharmaceuticals Creates Competitive Pressures

Growing Geriatric Population with High Cancer Susceptibility Propels Demand for Sunitinib Malate

Rising Healthcare Expenditure in Emerging Economies Boosts Market Penetration

4. GLOBAL MARKET PERSPECTIVE

World Recent Past, Current & Future Analysis for Above 99% Purity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Above 99% Purity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Above 98% Purity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Above 98% Purity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Above 97% Purity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Above 97% Purity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Pancreatic Neuroendocrine Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Pancreatic Neuroendocrine Tumor Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Gastrointestinal Stromal Tumor Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Gastrointestinal Stromal Tumor Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Kidney Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Kidney Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Sunitinib Malate Market Analysis of Annual Sales in US$ for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Sunitinib Malate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Sunitinib Malate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

USA 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

USA Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

USA 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Canada 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

Canada Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Canada 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

JAPAN

Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Japan 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

Japan Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Japan 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

CHINA

Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

China 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

China Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

China 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

EUROPE

Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Europe 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Europe 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR

Europe 6-Year Perspective for Sunitinib Malate by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030

FRANCE

Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

France 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

France Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

France 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

GERMANY

Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Germany 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

Germany Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Germany 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Italy 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

Italy Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Italy 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

UNITED KINGDOM

Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

UK 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

UK Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

UK 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Rest of Europe 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Rest of Europe 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

ASIA-PACIFIC

Sunitinib Malate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Asia-Pacific 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Asia-Pacific 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Sunitinib Malate by Purity Level - Above 99% Purity, Above 98% Purity and Above 97% Purity - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Rest of World 6-Year Perspective for Sunitinib Malate by Purity Level - Percentage Breakdown of Value Sales for Above 99% Purity, Above 98% Purity and Above 97% Purity for the Years 2025 & 2030

Rest of World Recent Past, Current & Future Analysis for Sunitinib Malate by Application - Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR

Rest of World 6-Year Perspective for Sunitinib Malate by Application - Percentage Breakdown of Value Sales for Pancreatic Neuroendocrine Tumor Application, Gastrointestinal Stromal Tumor Application and Kidney Cancer Application for the Years 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Active Biotech AB	%
Astellas Pharma, Inc.	%
Bristol-Myers Squibb Company	%
Changzhou Highassay Chemical Co., Ltd	%
Dendreon Pharmaceuticals LLC	%
Ferring Pharmaceuticals Inc	%
Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.	%
Medichem, S.A.	%
Pfizer, Inc.	%
Teva Pharmaceutical Industries Ltd.	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll